TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05260047

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IMANI
Description: For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMANI
Description: For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMANI
Description: For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth MAT
Description: Describe what is the Telehealth MAT briefly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional MAT plus Referral and Linkage
Description: Describe what he traditional MAT plus referral and linkage briefly
Study: NCT06320054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Health Management Program
Description: Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
Study: NCT04028713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dried blood spot
Description: A subset of patients will sample additionally by using the dried blood sampling technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dried blood spot
Description: A subset of patients will sample additionally by using the dried blood sampling technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose reduction
Description: Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
Study: NCT05231226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediately CR
Description: Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged (within 45 days) CR
Description: Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
Study: NCT04939766

Intervention type: DEVICE
Group type: OTHER
Intervention: Activation of a closed loop device in an insulin pump device with GCM
Description: After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
Study: NCT05659108

Intervention type: BEHAVIORAL
Intervention: CPR
Description: HIGH QUALITY CPR

Intervention type: BEHAVIORAL
Intervention: CPR
Description: HIGH QUALITY CPR
Study: NCT06009965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA+ATG+Herombopag
Description: CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA+Herombopag
Description: CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
Study: NCT06416306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Intervention
Description: The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Intervention
Description: The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.
Study: NCT05236517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 2
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 3
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C Dose 5 (50 mg)
Description: Tablet given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide C)
Description: Tablet given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( Semaglutide D)
Description: Tablet given orally
Study: NCT05690984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
Study: NCT04874714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09-MG01(30.000-30.000)
Description: Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG01(30.000)
Description: Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09(30.000)
Description: Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
Study: NCT06455228

Intervention type: DEVICE
Group type: OTHER
Intervention: insert catheter
Description: A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insert catheter
Description: A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
Study: NCT06552871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forming Love around Autistic People to Prevent Suicide
Description: Four-part virtual educational intervention
Study: NCT06216925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #BabyLetsMove
Description: Description of #BabyLetsMove

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WIC Antenatal Care
Description: Description
Study: NCT06255275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurocognitifs tests + pedestrian crossign whith virtual reality
Description: Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
Study: NCT05071209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO
Study: NCT06209658

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: breastfeeding education of Teach Back
Description: breastfeeding education simple explanation is given and the woman is asked to explain and practice.

Intervention type: OTHER
Group type: OTHER
Intervention: breastfeeding education simple explanation
Description: breastfeeding education simple explanation
Study: NCT05036252

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
Study: NCT05939414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
Study: NCT06061991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile instant messaging-based lifestyle intervention
Description: Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging reminders
Description: Follow-up reminders via text messaging as attention control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice on GDM prevention
Description: Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice on GDM prevention
Description: Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by the prenatal clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care provided by the prenatal clinic.
Study: NCT06044675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA assisted psychotherapy
Description: This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
Study: NCT06069128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurotrigger Basic. eye blinking stimulator
Description: NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
Study: NCT06000137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Flurbiprofen for patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Injection
Description: granisetron has antiemetic function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Injection
Description: granisetron has antiemetic function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Injection
Description: granisetron has antiemetic function.
Study: NCT06248099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol-Test product
Description: Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol-Reference product
Description: Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
Study: NCT06595043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the tip opening angle to the left
Description: After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: the tip opening angle to the right
Description: After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
Study: NCT06303960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Cerebellar deep brain stimulation
Description: Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Cerebellar deep brain stimulation
Description: Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
Study: NCT06592404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Tessa
Description: Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Tessa
Description: Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Tessa
Description: Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Tessa
Description: Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale.
Study: NCT06062420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelistotug
Description: Nelistotug will be administered.
Study: NCT05087979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stable airway management (SAM) device
Description: SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
Study: NCT05415943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic microprobe (inPROBE) medical device
Description: Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
Study: NCT04558879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT
Description: 12 weeks of exercise Cardiovascular Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT
Description: 12 weeks of exercise Resistance Training